Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | BCAT1 | P54687 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978077 | 0.89 | PTGES (0.50) | PTGESTP53MAPTCA2CA1 | |
| SCHEMBL979269 | 0.89 | PTGES (0.49) | PTGESTP53MAPTCA2CA1 | |
| SCHEMBL979350 | 0.80 | PTGES (0.45) | PTGESTP53MAPTCA2CA1 | |
| SCHEMBL978370 | 0.79 | HDAC6 (0.48) | PTGESTP53MAPTCA2CA1 | |
| SCHEMBL981401 | 0.79 | PTGES (0.52) | PTGESTP53MAPTHDAC6 | |
| SCHEMBL976561 | 0.79 | PTGES (0.53) | PTGESCA2CA1CA9HDAC6 | |
| SCHEMBL2899899 | 0.79 | PTGES (0.43) | PTGESTP53MAPTCA2CA1 | |
| SCHEMBL977985 | 0.78 | HDAC6 (0.57) | PTGESTP53MAPTCA2CA1 | |
| SCHEMBL978821 | 0.77 | PTGES (0.48) | PTGESTP53CA2CA1CA9 | |
| SCHEMBL979375 | 0.76 | PTGES (0.47) | PTGESCA2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | claimed |
| EP-2217566-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | claimed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | claimed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | claimed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | claimed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | claimed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| EP-2217566-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | PTGES 9/4885TP53 2963/4885MAPT 981/4885 |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | PTGES 13/4885TP53 2337/4885MAPT 1161/4885 |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | PTGES 13/4885TP53 2337/4885MAPT 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.